Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 147.11M P/E - EPS this Y 26.90% Ern Qtrly Grth -
Income -44.9M Forward P/E -1.98 EPS next Y -26.30% 50D Avg Chg 6.00%
Sales 7.26M PEG - EPS past 5Y - 200D Avg Chg -43.00%
Dividend N/A Price/Book 1.71 EPS next 5Y - 52W High Chg -81.00%
Recommedations 2.00 Quick Ratio 0.87 Shares Outstanding 287.86M 52W Low Chg 30.00%
Insider Own 1.41% ROA -49.82% Shares Float 283.91M Beta 3.73
Inst Own 23.52% ROE -114.42% Shares Shorted/Prior 50.90M/51.27M Price 0.57
Gross Margin - Profit Margin - Avg. Volume 7,785,711 Target Price 7.00
Oper. Margin -1,353.99% Earnings Date Nov 7 Volume 3,810,886 Change -5.14%
About Ocugen, Inc.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Ocugen, Inc. News
11/20/24 Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
11/19/24 Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
11/14/24 Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
11/14/24 Ocugen: Q3 Earnings Snapshot
11/09/24 Q3 2024 Ocugen Inc Earnings Call
11/09/24 Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
11/08/24 Ocugen (OCGN) Q3 2024 Earnings Call Transcript
11/08/24 Ocugen Provides Business Update with Third Quarter 2024 Financial Results
11/07/24 Ocugen Secures $30 Million in Debt Funding
10/31/24 Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%
10/28/24 Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
10/22/24 Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
10/17/24 Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
10/16/24 State Street Corp's Strategic Acquisition of Shares in Ocugen Inc
10/10/24 Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
10/09/24 Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
10/09/24 Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
10/02/24 Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
09/24/24 Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
09/09/24 Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
OCGN Chatroom

User Image TouchHoole Posted - 4 hours ago

$OCGN https://www.facebook.com/share/r/17Ua3X4Fyv/

User Image VINCENZOCOCCOTTI Posted - 4 hours ago

$OCGN https://www.foxnews.com/politics/trump-picks-dr-marty-makary-food-drug-administration-commissioner

User Image MTEverest888 Posted - 4 hours ago

$OCGN 🫑🫑🫑🫑🫑🫑🫑🫑😎 TRUELONG$ ARE STILL HERE...NOT SELLING!!!🦍🦖🐉 🩳🐻's 🍼🍼🍼

User Image charleychap Posted - 5 hours ago

$OCGN The journey is part of the fun..

User Image hotsoss Posted - 6 hours ago

$OCGN

User Image Jpred Posted - 6 hours ago

$OCGN when was started below one dollar ? If cross 6 months then get compliance notice .

User Image Moneybags1994 Posted - 7 hours ago

$OCGN anyone here from the old days?

User Image Slapshot22 Posted - 9 hours ago

$OCGN I wish posters spent more time articulating a logical reason for their PoV and a little less time posting cartoons. But hey, it’s an open forum. Maybe cartoons impact some investors. Scary thought.

User Image SGimvesting Posted - 9 hours ago

$OCGN next week?

User Image Beanie_Mojo Posted - 10 hours ago

$OCGN

User Image Snow120 Posted - 10 hours ago

$OCGN still 💩 below $1

User Image CasaDePapel Posted - 10 hours ago

$OCGN tomorrow $8

User Image Dfwmb Posted - 11 hours ago

$OCGN yea. Added two more up to 186. Maybe they are selling to each other.

User Image rgb8 Posted - 11 hours ago

$OCGN

User Image Manuelitos Posted - 11 hours ago

$OCGN 🕺🕺

User Image TheMarketSavant Posted - 12 hours ago

$OCGN Likely Scenarios for Market Cap and Stock Price Based solely on NeoCart: 1. If Ocugen’s NeoCart therapy shows positive clinical trial results, especially in Phase 3 or pivotal trials, this would be a major catalyst for the stock. If the therapy progresses smoothly through the FDA approval process, it could lead to significant growth. A successful clinical trial and approval could dramatically increase the stock price, possibly seeing double or triple-digit percentage gains. The biotech sector tends to see sharp price movements in response to news about drug approvals or successful trials. Market cap could increase significantly, potentially moving it into the range of $1 billion to $3 billion or more, depending on the success and market potential of NeoCart. This range is based on the typical valuation of mid-stage biotech companies that have successful therapies on the cusp of approval, though larger pharma companies with strong financial backing could push the cap even higher.

User Image Djtrush Posted - 12 hours ago

$OCGN When this hits, I’m getting some socks and undies

User Image simbha Posted - 12 hours ago

$OCGN stock consultant :

User Image hotsoss Posted - 12 hours ago

$OCGN explain this … tutes selling away. Bunch of junk

User Image WantonSugar Posted - 12 hours ago

$OCGN Look at all those tutes....Selling.

User Image SGimvesting Posted - 12 hours ago

$OCGN if it goes to a dollar today I’ll go away and never come back for a couple hours.

User Image redwoodberry Posted - 12 hours ago

$OCGN not looking good...

User Image Jag2441 Posted - 13 hours ago

$OCGN starting to look like a pre-Biden market.

User Image SPOON03 Posted - 13 hours ago

$OCGN 🥱

User Image giglio75 Posted - 13 hours ago

$OCGN today under 2 millions

User Image crazysnake Posted - 14 hours ago

$PFE take a look a ocugen could be a great stock for a buyout $OCGN

User Image charleychap Posted - 14 hours ago

$OCGN How easy is Ocugen treatment? One and done...

User Image Beanie_Mojo Posted - 14 hours ago

$OCGN Flip a copper pennie burger 🪙 We got you ! 😂

User Image Bigcrank15 Posted - 14 hours ago

$OCGN Almost that time again for me to buy more. I like this stock! The load zone pricing has been great.

User Image Dfwmb Posted - 14 hours ago

$OCGN alrighty… caught a little run in Rcat over the past days. Shows what can happen if you sit and wait! Even if you don’t remember why you bought shares. Smile!

Analyst Ratings
Chardan Capital Buy May 15, 24
HC Wainwright & Co. Buy May 15, 24
Chardan Capital Buy Apr 22, 24
HC Wainwright & Co. Buy Apr 3, 24
HC Wainwright & Co. Buy Feb 22, 24
HC Wainwright & Co. Buy Jan 24, 24
Cantor Fitzgerald Overweight Aug 31, 23
HC Wainwright & Co. Buy Aug 23, 23
Chardan Capital Buy May 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Musunuri Shankar Chief Executive Offi.. Chief Executive Officer Jan 17 Sell 1.28 100,000 128,000 2,227,950 01/19/23
Musunuri Shankar Chief Executive Offi.. Chief Executive Officer Jan 17 Option 0.51 100,000 51,000 2,327,950 01/19/23
Kumar Ramesh Director Director Apr 18 Option 0.51 7,500 3,825 7,500 04/20/22
Kumar Ramesh Director Director Apr 18 Sell 2.83 7,500 21,225 04/20/22
Zhang Junge Director Director Mar 03 Option 1.17 88,000 102,960 88,000 03/04/22
Musunuri Shankar Chief Executive Offi.. Chief Executive Officer Feb 14 Option 0.33 90,000 29,700 842,540 02/16/22
Musunuri Shankar Chief Executive Offi.. Chief Executive Officer Feb 14 Sell 3.74 90,000 336,600 752,540 02/16/22
Potti Manish Director Director Dec 16 Option 1.17 45,000 52,650 45,000 12/17/21
Kompella Uday Director Director Nov 01 Sell 15.03 50,000 751,500 154,416 11/03/21
Musunuri Shankar Chief Executive Offi.. Chief Executive Officer Nov 01 Option 0.51 115,367 58,837 521,367 11/03/21
Musunuri Shankar Chief Executive Offi.. Chief Executive Officer Nov 01 Sell 14.15 115,367 1,632,443 406,000 11/03/21
Kompella Uday Director Director Oct 18 Sell 8.72 201,731 1,759,094 277,685 10/20/21
Kumar Ramesh Director Director Oct 18 Option 0.51 7,500 3,825 7,500 10/20/21
Kumar Ramesh Director Director Oct 18 Sell 8.13 7,500 60,975 10/20/21
Kompella Uday Director Director Jul 30 Option 1.83 10,000 18,300 560,674 07/30/21